Bio Green Med Solution, Inc. 10-Q

Item 5. Other Information None. Item 6. Exhibits Exhibit Number Description 31.1* ​ Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a) As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* ​ Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a) As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 . 32.2* Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 . 101 ​ The following materials from Cyclacel Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements. 104 ​ The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline eXtensible Business Reporting Language (included with Exhibit 101). ​ ​ ​ * Filed herewith. ​ ​ ​ 30 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned. ​ ​ ​ ​ ​ CYCLACEL PHARMACEUTICALS, INC. ​ ​ ​ ​ Date: November 10, 2022 ​ By: /s/ Paul McBarron ​ ​ ​ Paul McBarron ​ ​ ​ Chief Operating Officer, Chief Financial Officer and Executive Vice President, Finance ​ ​ ​ 31